Compare KLA Corp. (KLAC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Organon & Co. Common Stock — how do they compare? KLA Corp. trades at $177.51 (market cap $240.12B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: KLA Corp. is far larger — about 66.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Organon & Co. Common Stock for 0 Days on average.
| KLAC | OGN | |
|---|---|---|
Market Cap | $240.12B | $3.62B |
Volume | 10,439,404 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $301.71 | $13.81 |
52-Week Low | $108.70 | $5.70 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $241.37B | $11.04B |
Dividend Yield | 0.5% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $178.81, down 5.95% on the day, amid a broader tech selloff. The stock maintains a bullish technical signal, with strong fundamentals including a 35.57% net income margin and consistent earnings beats. Revenue reached $12.16B in 2025, with a robust backlog of $12.57B driven by AI demand, positioning the company for growth in semiconductor equipment.
The outlook remains positive with a consensus price target of $223.88, implying significant upside. Risks include competitive pressures from Applied Materials and ASML, and sensitivity to semiconductor capex cycles. Analyst sentiment is strongly bullish, with 28 buy ratings, supporting a favorable long-term investment case despite near-term volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
